bluuebunny/crossref_metadata_2025 huggingface dataset:
CD73 Is a Critical Immune Checkpoint in a Molecular Subtype of Pancreatic Cancer
Authors: DelGiorno Kathleen
Published: April 2023

Molecular stratification of patients with pancreatic ductal adenocarcinoma (PDAC) has the potential to guide clinical decision-making for therapeutic intervention. Investigating mechanisms by which different molecular subtypes of PDAC form and progress will improve patient responses to existing therapies and aid in identifying new, more specific therapeutic approaches. In this issue of Cancer Research, Faraoni and colleagues identified CD73/Nt5e-generated adenosine as a mechanism of immunosuppression specifically in pancreatic ductal–derived basal/squamous-type PDAC. Using genetically engineered mouse models targeting key genetic mutations to pancreatic acinar or ductal cells and an array of experimental and computational biology approaches, the authors found that adenosine signaling through receptor ADORA2B induces immunosuppression and tumor progression in ductal cell–derived tumors. These data demonstrate how molecular stratification of PDAC in combination with targeted approaches may enhance patient responses to therapy in this deadly cancer.

See related article by Faraoni et al., p. 1111
Data from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Authors: Wildsmith Sophie , Li Weimin , Wu Song , Stewart Ross , Morsli Nassim , Raja Rajiv , Zhang Qu , Ye Jiabu , He Philip , Shetty Jagdish , Yovine Alejandro , Holoweckyj Nicholas , Real Katia , Walker Jill , Wrona Magdalena , de los Reyes Melissa , Barker Craig , Whiteley Jessica , Haddad Robert , Licitra Lisa , Ferris Robert , Fayette Jérôme , Zandberg Dan P. , Siu Lillian L. , Mesía Ricard
Published: April 2023

AbstractPurpose:
Biomarkers that predict response to immune checkpoint inhibitors (ICI) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) are needed. This retrospective study assessed tumor mutational burden (TMB) and outcomes in the phase II HAWK and CONDOR and phase III EAGLE studies of durvalumab with or without tremelimumab in platinum-resistant R/M HNSCC.
Patients and Methods:
Tumor samples from HAWK/CONDOR (N = 153) and blood samples from EAGLE (N = 247) were analyzed for TMB. Associations with survival were evaluated for tissue TMB (tTMB) at cutoffs from 10 to 20 mutations/megabase (mut/Mb) and for blood plasma TMB (bTMB) at cutoffs from 8 to 24 mut/Mb.
Results:
In HAWK/CONDOR, overall survival (OS) with durvalumab with or without tremelimumab was longer for high versus low tTMB: statistically significant differences were observed with durvalumab plus tremelimumab at tTMB ≥ 10 mut/Mb [HR, 0.52 (95% confidence interval, CI, 0.28–0.98)] and tTMB ≥ 12 mut/Mb [HR, 0.46 (95% CI, 0.24–0.86)]. In EAGLE, a significant OS benefit versus chemotherapy was observed with durvalumab and durvalumab plus tremelimumab at bTMB≥16 mut/Mb [HR, 0.39 (95% CI, 0.20–0.76) and 0.38 (95% CI, 0.19–0.78), respectively] but not bTMB < 16 mut/Mb [HR, 0.92 (0.61–1.37) and 0.92 (95% CI, 0.62–1.36), respectively]. A significant progression-free survival benefit was also observed in the ICI arms versus chemotherapy at bTMB ≥ 16 mut/Mb.
Conclusions:
Findings support TMB as a biomarker for predicting survival in patients with platinum-resistant R/M HNSCC treated with ICIs. The analysis of EAGLE demonstrated that bTMB was predictive of survival with ICI treatment versus chemotherapy in a large, randomized controlled study population.
Proteostasis Modulation in Germline Missense von Hippel Lindau Disease
Authors: Chittiboina Prashant , Mandal Debjani , Bugarini Alejandro , Asuzu David T. , Mullaney Dustin , Mastorakos Panagiotis , Stoica Stefan , Alvarez Reinier , Scott Gretchen , Maric Dragan , Elkahloun Abdel , Zhuang Zhengping , Chew Emily Y. , Yang Chunzhang , Linehan Marston , Lonser Russell R.
Published: April 2023

Purpose:

Missense mutated von Hippel Lindau (VHL) protein (pVHL) maintains intrinsic function but undergoes proteasomal degradation and tumor initiation and/or progression in VHL disease. Vorinostat can rescue missense mutated pVHL and arrest tumor growth in preclinical models. We asked whether short-term oral vorinostat could rescue pVHL in central nervous system hemangioblastomas in patients with germline missense VHL.

Patients and Methods:

We administered oral vorinostat to 7 subjects (ages 46.0 ± 14.5 years) and then removed symptomatic hemangioblastomas surgically (ClinicalTrials.gov identifier NCT02108002).

Results:

Vorinostat was tolerated without serious adverse events by all patients. pVHL expression was elevated in neoplastic stromal cells compared with untreated hemangioblastomas from same patients. We found transcriptional suppression of downstream hypoxia-inducible factor (HIF) effectors. Mechanistically, vorinostat prevented Hsp90 recruitment to mutated pVHL in vitro. The effects of vorinostat on the Hsp90–pVHL interaction, pVHL rescue, and transcriptional repression of downstream HIF effectors was independent of the location of the missense mutation on the VHL locus. We confirmed a neoplastic stromal cell–specific effect in suppression of protumorigenic pathways with single-nucleus transcriptomic profiling.

Conclusions:

We found that oral vorinostat treatment in patients with germline missense VHL mutations has a potent biologic effect that warrants further clinical study. These results provide biologic evidence to support the use of proteostasis modulation for the treatment of syndromic solid tumors involving protein misfolding. Proteostasis modulation with vorinostat rescues missense mutated VHL protein. Further clinical trials are needed to demonstrate tumor growth arrest.
Supplementary Figure 4 from Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9
Authors: Dolloff Nathan G. , Allen Joshua E. , Dicker David T. , Aqui Nicole , Vogl Dan , Malysz Jozef , Talamo Giampaolo , El-Deiry Wafik S.
Published: April 2023

PDF file, 66K, SLM6 does not inhibit PKC signaling at drug concentrations that induce death of MM cells.
Supplementary Figure 1 from Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment
Authors: Stokes Jayme B. , Adair Sara J. , Slack-Davis Jill K. , Walters Dustin M. , Tilghman Robert W. , Hershey E. Dan , Lowrey Bryce , Thomas Keena S. , Bouton Amy H. , Hwang Rosa F. , Stelow Edward B. , Parsons J. Thomas , Bauer Todd W.
Published: April 2023

PDF file - 48K
Supplementary Figure 1 from Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models
Authors: Sharkey Robert M. , Karacay Habibe , Govindan Serengulam V. , Goldenberg David M.
Published: April 2023

Supplementary Figure 1 from Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models
Supplementary Figure 2 from PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
Authors: Yuan Jing , Mehta Pramod P. , Yin Min-Jean , Sun Shaoxian , Zou Aihua , Chen Jeffrey , Rafidi Kristina , Feng Zheng , Nickel Jeffrey , Engebretsen Jon , Hallin Jill , Blasina Alessandra , Zhang Eric , Nguyen Leslie , Sun Minghao , Vogt Peter K. , McHarg Aileen , Cheng Hengmiao , Christensen James G. , Kan Julie L.C. , Bagrodia Shubha
Published: April 2023

PDF file - 271K
Supplementary Tables 1-4 from A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression
Authors: van Zijl Franziska , Mall Sabine , Machat Georg , Pirker Christine , Zeillinger Robert , Weinhaeusel Andreas , Bilban Martin , Berger Walter , Mikulits Wolfgang
Published: April 2023

Supplementary Tables 1-4 from A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression
Supplementary Figure 1 from An Antibody Fusion Protein for Cancer Immunotherapy Mimicking IL-15 trans-Presentation at the Tumor Site
Authors: Kermer Vanessa , Baum Volker , Hornig Nora , Kontermann Roland E. , Müller Dafne
Published: April 2023

PDF file, 42KB, supplemental data, S2, HPLC analysis data.
Supplementary Figure 4 from Smoking Induces Epithelial-to-Mesenchymal Transition in Non–Small Cell Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin
Authors: Nagathihalli Nagaraj S. , Massion Pierre P. , Gonzalez Adriana L. , Lu Pengcheng , Datta Pran K.
Published: April 2023

PDF file, 152K, LEF-1 and Slug knockdown and E-cadh expression in LEF-1 and Slug knockdown clones.
Supplementary Figure 1 from Smoking Induces Epithelial-to-Mesenchymal Transition in Non–Small Cell Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin
Authors: Nagathihalli Nagaraj S. , Massion Pierre P. , Gonzalez Adriana L. , Lu Pengcheng , Datta Pran K.
Published: April 2023

PDF file, 66K, Correlation between E-cadh index score and pack-years.
Supplementary Figure 1 from Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma
Authors: Keating Joanna , Tsoli Maria , Hallahan Andrew R. , Ingram Wendy J. , Haber Michelle , Ziegler David S.
Published: April 2023

PDF file - 65K, Treatment with cisplatin and radiation therapy increases IAP gene expression in additional medulloblastoma cell lines
Supplementary Materials from Targeting Plasminogen Activator Inhibitor-1 Inhibits Angiogenesis and Tumor Growth in a Human Cancer Xenograft Model
Authors: Gomes-Giacoia Evan , Miyake Makito , Goodison Steve , Rosser Charles J.
Published: April 2023

PDF - 89KB, Supplementary materials.
Supplementary Figure 5 from Targeting Plasminogen Activator Inhibitor-1 Inhibits Angiogenesis and Tumor Growth in a Human Cancer Xenograft Model
Authors: Gomes-Giacoia Evan , Miyake Makito , Goodison Steve , Rosser Charles J.
Published: April 2023

PDF - 2987KB, Tumor growth was established by subcutaneous injection of parental HeLa cells into athymic nude mice (nu/nu) followed by the oral administration of tiplaxtinin at two different doses as described in Materials and Methods. Corn oil administered orally served as control. A, HeLa tumor sizes were recorded over five weeks. The relative tumor size was plotted as mean + SD from the three treatment groups per cell line (n=10/group). Treatment with tiplaxtinin (5 mg/kg and 20 mg/kg) was associated with a reduction in HeLa tumor burden. B, H&E and PAI-1 staining of HeLa tumors are shown (images 200X). A reduction in PAI-1 expression was noted in HeLa tumors treated with tiplaxtinin. C, Microvessel density (MVD) was quantified based on CD31 staining as previously reported (22). Proliferative index (PI) was quantified based on Ki-67 staining as previously reported (22). Apoptotic index (AI) was quantified based on cleaved caspase-3 staining as previously reported (22). Tiplaxtinin treatment of xenografts was associated with a reduction in angiogenesis and proliferation with an accompanied induction of apoptosis. Data from one representative experiment are presented as mean + SD. *, p < 0.05.
Supplementary Table 2 from Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion
Authors: Saintigny Pierre , Peng Shaohua , Zhang Li , Sen Banibrata , Wistuba Ignacio I. , Lippman Scott M. , Girard Luc , Minna John D. , Heymach John V. , Johnson Faye M.
Published: April 2023

PDF file, 94K, Multicovariate analysis showing the association between ephrin receptor and ephrin gene expression and overall survival or relapse-free survival in patients resected for a lung adenocarcinoma.
Supplementary Methods from Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion
Authors: Saintigny Pierre , Peng Shaohua , Zhang Li , Sen Banibrata , Wistuba Ignacio I. , Lippman Scott M. , Girard Luc , Minna John D. , Heymach John V. , Johnson Faye M.
Published: April 2023

PDF file, 102K, Supplementary Material and Methods for gene expression analysis are provided.
Supplementary Table 4 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Authors: Craig David W. , O'Shaughnessy Joyce A. , Kiefer Jeffrey A. , Aldrich Jessica , Sinari Shripad , Moses Tracy M. , Wong Shukmei , Dinh Jennifer , Christoforides Alexis , Blum Joanne L. , Aitelli Cristi L. , Osborne Cynthia R. , Izatt Tyler , Kurdoglu Ahmet , Baker Angela , Koeman Julie , Barbacioru Catalin , Sakarya Onur , De La Vega Francisco M. , Siddiqui Asim , Hoang Linh , Billings Paul R. , Salhia Bodour , Tolcher Anthony W. , Trent Jeffrey M. , Mousses Spyro , Von Hoff Daniel , Carpten John D.
Published: April 2023

XLSX file - 42K, Ingenuity Canonical Pathways results for mTNBC based on edgeR differential expression results
Supplementary Figure 8 from Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion
Authors: Saintigny Pierre , Peng Shaohua , Zhang Li , Sen Banibrata , Wistuba Ignacio I. , Lippman Scott M. , Girard Luc , Minna John D. , Heymach John V. , Johnson Faye M.
Published: April 2023

PDF file, 68K, EPHA4 effect on drug sensitivity.
Supplementary Table 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Authors: Craig David W. , O'Shaughnessy Joyce A. , Kiefer Jeffrey A. , Aldrich Jessica , Sinari Shripad , Moses Tracy M. , Wong Shukmei , Dinh Jennifer , Christoforides Alexis , Blum Joanne L. , Aitelli Cristi L. , Osborne Cynthia R. , Izatt Tyler , Kurdoglu Ahmet , Baker Angela , Koeman Julie , Barbacioru Catalin , Sakarya Onur , De La Vega Francisco M. , Siddiqui Asim , Hoang Linh , Billings Paul R. , Salhia Bodour , Tolcher Anthony W. , Trent Jeffrey M. , Mousses Spyro , Von Hoff Daniel , Carpten John D.
Published: April 2023

XLSX file - 40K, Characteristics of mTNBC study population
Supplementary Figure 6 from Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion
Authors: Saintigny Pierre , Peng Shaohua , Zhang Li , Sen Banibrata , Wistuba Ignacio I. , Lippman Scott M. , Girard Luc , Minna John D. , Heymach John V. , Johnson Faye M.
Published: April 2023

PDF file, 726K, EPHA4 and morphology.
Supplementary Table 4 from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo
Authors: Kuruma Hidetoshi , Matsumoto Hiroaki , Shiota Masaki , Bishop Jennifer , Lamoureux Francois , Thomas Christian , Briere David , Los Gerrit , Gleave Martin , Fanjul Andrea , Zoubeidi Amina
Published: April 2023

PDF, 49K, AR transcriptional activity EC50 in MR49F cells treated with MDV3100 and Compound 30
Supplementary Table 6 from Pharmacogenomic Profiling and Pathway Analyses Identify MAPK-Dependent Migration as an Acute Response to SN38 in p53 Null and p53-Mutant Colorectal Cancer Cells
Authors: Allen Wendy L. , Turkington Richard C. , Stevenson Leanne , Carson Gail , Coyle Vicky M. , Hector Suzanne , Dunne Philip , Van Schaeybroeck Sandra , Longley Daniel B. , Johnston Patrick G.
Published: April 2023

PDF file - 35K, Real-time PCR validation of HCT116 p53 null cells following treatment with 5nM SN38 for 6, 12 and 24h. This table shows the Pearson's correlation and p values for each individual gene
Supplementary Table 1 from Y-box Binding Protein-1 Contributes to Both HER2/ErbB2 Expression and Lapatinib Sensitivity in Human Gastric Cancer Cells
Authors: Shibata Tomohiro , Kan Hitoshi , Murakami Yuichi , Ureshino Hiroki , Watari Kosuke , Kawahara Akihiko , Kage Masayoshi , Hattori Satoshi , Ono Mayumi , Kuwano Michihiko
Published: April 2023

PDF File - 66K, Sensitivity to lapatinib, erlotinib, SU11274, cisplatin and CPT-11 in human gastric cancer cell lines.
Supplementary Methods from Off-Target Function of the Sonic Hedgehog Inhibitor Cyclopamine in Mediating Apoptosis via Nitric Oxide–Dependent Neutral Sphingomyelinase 2/Ceramide Induction
Authors: Meyers-Needham Marisa , Lewis Jocelyn A. , Gencer Salih , Sentelle R. David , Saddoughi Sahar A. , Clarke Christopher J. , Hannun Yusuf A. , Norell Haakan , da Palma Telma Martins , Nishimura Michael , Kraveka Jacqueline M. , Khavandgar Zohreh , Murshed Monzur , Cevik M. Ozgur , Ogretmen Besim
Published: April 2023

PDF file, 101KB.
Supplementary Figure 1 from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo
Authors: Christoph Sandra , DeRyckere Deborah , Schlegel Jennifer , Frazer J. Kimble , Batchelor Lance A. , Trakhimets Alesia Y. , Sather Susan , Hunter Debra M. , Cummings Christopher T. , Liu Jing , Yang Chao , Kireev Dmitri , Simpson Catherine , Norris-Drouin Jacqueline , Hull-Ryde Emily A. , Janzen William P. , Johnson Gary L. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Graham Douglas K.
Published: April 2023

PDF - 294KB, TAM receptor expression in Jurkat cell line was detected by western blot analysis. Whole cell lysates were prepared and phosphorylated (denoted by p-) and total proteins were detected. Western blots representative of three independent experiments are shown. Blots were stripped and reprobed with anti-tubulin antibody to confirm similar protein loading.
Supplementary Figure 3 from The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Authors: Carden Craig P. , Stewart Adam , Thavasu Parames , Kipps Emma , Pope Lorna , Crespo Mateus , Miranda Susana , Attard Gerhardt , Garrett Michelle D. , Clarke Paul A. , Workman Paul , de Bono Johann S. , Gore Martin , Kaye Stan B , Banerji Udai
Published: April 2023

PDF file, 44KB, Probes for PIK3CA, AKT2 and PTEN.
Supplementary Figure 7 from Apigenin Sensitizes Colon Cancer Cells to Antitumor Activity of ABT-263
Authors: Shao Huanjie , Jing Kai , Mahmoud Esraa , Huang Haihong , Fang Xianjun , Yu Chunrong
Published: April 2023

PDF - 1353KB, Supplementary Figure S7. Inactivation of AKT and/or ERK resulted in upregulation of Bim-L.
Supplementary Tables from Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance
Authors: Haider Christine , Grubinger Markus , Řezníčková Eva , Weiss Thomas S. , Rotheneder Hans , Miklos Walter , Berger Walter , Jorda Radek , Zatloukal Marek , Gucký Tomáš , Strnad Miroslav , Kryštof Vladimír , Mikulits Wolfgang
Published: April 2023

PDF file, 227K, Suppl. table S1: IC50 values Suppl. table S2: Substrate specificity.
Supplementary Figure 2 from Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance
Authors: Haider Christine , Grubinger Markus , Řezníčková Eva , Weiss Thomas S. , Rotheneder Hans , Miklos Walter , Berger Walter , Jorda Radek , Zatloukal Marek , Gucký Tomáš , Strnad Miroslav , Kryštof Vladimír , Mikulits Wolfgang
Published: April 2023

PDF file, 169K, Viability of treated hepatoma cells.
Supplementary Figure 1 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
Authors: Avan Amir , Crea Francesco , Paolicchi Elisa , Funel Niccola , Galvani Elena , Marquez Victor E , Honeywell Richard J. , Danesi Romano , Peters Godefridus J. , Giovannetti Elisa
Published: April 2023

PDF file, 694KB, Effects of DZNeP/gemcitabine combination on PDAC cells migration.
Supplementary Table S2 from Antitumor Activity and Pharmacodynamic Biomarkers of a Novel and Orally Available Small-Molecule Antagonist of Inhibitor of Apoptosis Proteins
Authors: Sumi Hiroyuki , Yabuki Masato , Iwai Kenichi , Morimoto Megumi , Hibino Ryosuke , Inazuka Masakazu , Hashimoto Kentaro , Kosugi Yohei , Aoyama Kazunobu , Yamamoto Shunsuke , Yoshimatsu Mie , Yamasaki Hideki , Tozawa Ryuichi , Ishikawa Tomoyasu , Yoshida Sei
Published: April 2023

PDF file - 32KB, Effects of T-3256336 in MDA-MB-231-Luc mice model
Supplementary Materials and Methods from Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
Authors: Huang Shyhmin , Peet Chimera R. , Saker Jarob , Li Chunrong , Armstrong Eric A. , Kragh Michael , Pedersen Mikkel W. , Harari Paul M.
Published: April 2023

PDF - 7KB, Quantification of EGFR mRNA expression.
Supplementary Figure Legends from Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
Authors: Huang Shyhmin , Peet Chimera R. , Saker Jarob , Li Chunrong , Armstrong Eric A. , Kragh Michael , Pedersen Mikkel W. , Harari Paul M.
Published: April 2023

PDF - 66KB, Legends for Supplementary Figures 1 and 2.
Supplementary Figure 1 from EGFR Inhibition Promotes an Aggressive Invasion Pattern Mediated by Mesenchymal-like Tumor Cells within Squamous Cell Carcinomas
Authors: Basu Devraj , Bewley Arnaud F. , Sperry Steven M. , Montone Kathleen T. , Gimotty Phyllis A. , Rasanen Kati , Facompre Nicole D. , Weinstein Gregory S. , Nakagawa Hiroshi , Diehl J. Alan , Rustgi Anil K. , Herlyn Meenhard
Published: April 2023

PDF file, 1027K, Mesenchymal-like cells in PDXs of SCCs with infiltrative invasion.
Supplementary Figure Legend from New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib
Authors: Wei Yinxiang , Ma Yuanfang , Zhao Qing , Ren Zhiguang , Li Yan , Hou Tingjun , Peng Hui
Published: April 2023

PDF file, 79KB.
Supplementary Figure 2 from New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib
Authors: Wei Yinxiang , Ma Yuanfang , Zhao Qing , Ren Zhiguang , Li Yan , Hou Tingjun , Peng Hui
Published: April 2023

PDF file, 173KB, Chemo-sensitization of drug resistance by sorafenib in the MCF7/MX cells.
Supplementary Figure 2 from Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling while Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells
Authors: Gunawardane Ruwanthi N. , Nepomuceno Ronald R. , Rooks Allison M. , Hunt Jeremy P. , Ricono Jill M. , Belli Barbara , Armstrong Robert C.
Published: April 2023

PDF file - 54K, DMSO and DR to quizartinib, percent apoptotic cells is percent of cells with <2N DNA
Supplementary Figure Legend from Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
Authors: Cho Hee-Yeon , Wang Weijun , Jhaveri Niyati , Torres Shering , Tseng Joshua , Leong Michelle N. , Lee David Jungpa , Goldkorn Amir , Xu Tong , Petasis Nicos A. , Louie Stan G. , Schönthal Axel H. , Hofman Florence M. , Chen Thomas C.
Published: April 2023

PDF file, 59K.
Supplementary Figure 3 from The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models
Authors: Ning Yan , Labonte Melissa J. , Zhang Wu , Bohanes Pierre O. , Gerger Armin , Yang Dongyun , Benhaim Leonor , Paez David , Rosenberg David O. , Nagulapalli Venkata Kalyan C. , Louie Stan G. , Petasis Nicos A. , Ladner Robert D. , Lenz Heinz-Josef
Published: April 2023

PDF file, 570K, ERCC1 mRNA expression in colon cancer cell lines.
Supplementary Figure 1 from The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models
Authors: Ning Yan , Labonte Melissa J. , Zhang Wu , Bohanes Pierre O. , Gerger Armin , Yang Dongyun , Benhaim Leonor , Paez David , Rosenberg David O. , Nagulapalli Venkata Kalyan C. , Louie Stan G. , Petasis Nicos A. , Ladner Robert D. , Lenz Heinz-Josef
Published: April 2023

PDF file, 770K, SCH-527123 treatment inhbits downstream activation of CXCR2 by decreasing phosphoryaltion of NF-kB and MAPK signaling cascades in CRC cell line models.
Supplementary Figure 5 from Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation
Authors: Kim Sun Mi , Kwon Oh-Joon , Hong Yun Kyoung , Kim Joo Hang , Solca Flavio , Ha Sang-Jun , Soo Ross A. , Christensen James G. , Lee Ji Hyun , Cho Byoung Chul
Published: April 2023

PDF file, 14K, Inactivation of c-MET by treatment of afatinib.
Supplementary Figure 4 from CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
Authors: Salas Fragomeni Roberto A. , Chung Hye Won , Landesman Yosef , Senapedis William , Saint-Martin Jean-Richard , Tsao Hensin , Flaherty Keith T. , Shacham Sharon , Kauffman Michael , Cusack James C.
Published: April 2023

Supplementary Figure 4 - PDF file 44K, CRM1 inhibition induces a statistically significant increase in caspase-3/7 activity as single therapy or in combination with BRAF inhibition
Supplementary Figure Legends and Supplementary Tables 1 and 2 from Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
Authors: Chiron Marielle , Bagley Rebecca G. , Pollard Jack , Mankoo Parminder K. , Henry Christophe , Vincent Loïc , Geslin Catherine , Baltes Nina , Bergstrom Donald A.
Published: April 2023

PDF - 115K, Legends to Supplementary Figures. Supplementary Table S1. Characteristics of 48 patient-derived colon cancer tumor xenografts. Supplementary Table S2. Evaluation of statistical differences between treatment(s) groups at the terminal point.
Supplementary Methods, Figure Legend from Small Molecule Inhibition of PAX3-FOXO1 through AKT Activation Suppresses Malignant Phenotypes of Alveolar Rhabdomyosarcoma
Authors: Jothi Mathivanan , Mal Munmun , Keller Charles , Mal Asoke K.
Published: April 2023

PDF file - 115K
Supplementary Methods, Supplementary Figures 1-5, and Supplementary Tables 1-2 from Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin
Authors: Pirie Christopher M. , Liu David V. , Wittrup K. Dane
Published: April 2023

PDF file- 129 KB, Supplementary Methods; Supplementary Figure S1: Potentiator binding and cytotoxicity; Supplementary Figure S2: Potentiator hemolytic activity; Supplementary Figure S3: Potentiation of gelonin immunotoxin cytotoxicity; Supplementary Figure S4: Potentiaion of internalized cytotoxicity and reduction of gelonin immunotoxin TN50; Supplementary Figure S5: Plasma clearance of immunotoxin and potentiators; Supplementary Table S1: Independent dose escalation of therapeutic proteins; Supplementary Table S2: Determination of the minimum delay between in vivo doses of synergistic agents.
Supplementary Fig. S2 from Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells
Authors: Tani Tetsuo , Yasuda Hiroyuki , Hamamoto Junko , Kuroda Aoi , Arai Daisuke , Ishioka Kota , Ohgino Keiko , Miyawaki Masayoshi , Kawada Ichiro , Naoki Katsuhiko , Hayashi Yuichiro , Betsuyaku Tomoko , Soejima Kenzo
Published: April 2023

Contribution of the EGFR pathway in H3122 and H3122-AR cells
Supplementary Figure 2 from Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss
Authors: Beauchamp Ellen M. , Woods Brittany A. , Dulak Austin M. , Tan Li , Xu Chunxiao , Gray Nathanael S. , Bass Adam J. , Wong Kwok-kin , Meyerson Matthew , Hammerman Peter S.
Published: April 2023

PDF - 61KB, Ectopic expression of IL6ST A664S or RNAi-mediated knockdown of EphA7 do not lead to a change in dasatinib sensitivity in NCI-H2286.
Supplementary Table 3 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Authors: Fu Maoyong , Maresh Erin L. , Helguera Gustavo F. , Kiyohara Meagan , Qin Yu , Ashki Negin , Daniels-Wells Tracy R. , Aziz Najib , Gordon Lynn K. , Braun Jonathan , Elshimali Yahya , Soslow Robert A. , Penichet Manuel L. , Goodglick Lee , Wadehra Madhuri
Published: April 2023

PDF - 51K, Supplementary Table 3. Expression levels of EMP2 in triple negative breast cancer.
Supplementary Table 2 from Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
Authors: Guzman Monica L. , Yang Neng , Sharma Krishan K. , Balys Marlene , Corbett Cheryl A. , Jordan Craig T. , Becker Michael W. , Steidl Ulrich , Abdel-Wahab Omar , Levine Ross L. , Marcucci Guido , Roboz Gail J. , Hassane Duane C.
Published: April 2023

PDF - 77K, DAVID pathway analysis for downregulated genes (KEGG pathways).
Supplementary Figure 5 from Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
Authors: Guzman Monica L. , Yang Neng , Sharma Krishan K. , Balys Marlene , Corbett Cheryl A. , Jordan Craig T. , Becker Michael W. , Steidl Ulrich , Abdel-Wahab Omar , Levine Ross L. , Marcucci Guido , Roboz Gail J. , Hassane Duane C.
Published: April 2023

PDF - 1495K, Quantification for the immunoblots shown in figure 5.
Supplementary Figure 3 from Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
Authors: Guzman Monica L. , Yang Neng , Sharma Krishan K. , Balys Marlene , Corbett Cheryl A. , Jordan Craig T. , Becker Michael W. , Steidl Ulrich , Abdel-Wahab Omar , Levine Ross L. , Marcucci Guido , Roboz Gail J. , Hassane Duane C.
Published: April 2023

PDF - 1783K, AR-42, unlike PTL, does not deplete thiols.
Supplementary Figure 2 from Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
Authors: Guzman Monica L. , Yang Neng , Sharma Krishan K. , Balys Marlene , Corbett Cheryl A. , Jordan Craig T. , Becker Michael W. , Steidl Ulrich , Abdel-Wahab Omar , Levine Ross L. , Marcucci Guido , Roboz Gail J. , Hassane Duane C.
Published: April 2023

PDF - 3889K, AR-42 demonstrates higher activity against a panel of leukemia cell lines in contrast to PTL
Supplementary Figure Legend from Decreased miR-340 Expression in Bone Marrow Is Associated with Liver Metastasis of Colorectal Cancer
Authors: Takeyama Hiroshi , Yamamoto Hirofumi , Yamashita Shinya , Wu Xin , Takahashi Hidekazu , Nishimura Junichi , Haraguchi Naotsugu , Miyake Yasuhiro , Suzuki Rei , Murata Kohei , Ohue Masayuki , Kato Takeshi , Takemasa Ichiro , Mizushima Tsunekazu , Ishii Hideshi , Mimori Koshi , Doki Yuichiro , Mori Masaki
Published: April 2023

PDF - 89K, Legends for Supplementary Figures 1 and 2.
Supplementary Figure 1 from Decreased miR-340 Expression in Bone Marrow Is Associated with Liver Metastasis of Colorectal Cancer
Authors: Takeyama Hiroshi , Yamamoto Hirofumi , Yamashita Shinya , Wu Xin , Takahashi Hidekazu , Nishimura Junichi , Haraguchi Naotsugu , Miyake Yasuhiro , Suzuki Rei , Murata Kohei , Ohue Masayuki , Kato Takeshi , Takemasa Ichiro , Mizushima Tsunekazu , Ishii Hideshi , Mimori Koshi , Doki Yuichiro , Mori Masaki
Published: April 2023

PDF - 135K, qRT-PCR for miR-340 and miR-542-3p in BM4 in patients with and without liver metastasis.
Supplementary Figures 1 - 6, Tables 1 - 3 from Anti-miR182 Reduces Ovarian Cancer Burden, Invasion, and Metastasis: An In Vivo Study in Orthotopic Xenografts of Nude Mice
Authors: Xu Xiaofei , Ayub Bushra , Liu Zhaojian , Serna Vanida Ann , Qiang Wenan , Liu Yugang , Hernando Eva , Zabludoff Sonya , Kurita Takeshi , Kong Beihua , Wei Jian-Jun
Published: April 2023

PDF file - 1679K, S Figure 1. Anti-miR-182 treatment for cell proliferation and invasion in normal and malignant ovarian cell lines in vitro. S Figure 2. Photomicrographs illustrating the surgical procedures of Orthotopic mouse model of ovarian cancer. S Figure 3. The general information of mice with anti-miR-182 treatment. S Figure 4. LIN28B, MYCN, and CA125 expression in mice with and without anti-miR-182 treatment. S Figure 5. Metastatic carcinomas in spleen and omentum. S Figure 6. Some miR-182 predicted target gene expression in mice with and without anti-miR-182 treatment. S Table 1. Primers and sequences used in this study. S Table 2. Antibody information used in this study. S Table 3. Metastasis analysis in mice with and without anti-miR-182 treatment.
Supplementary Figure 6 from 1α,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling
Authors: Chen Ping-Tsung , Hsieh Ching-Chuan , Wu Chun-Te , Yen Tzu-Chen , Lin Paul-Yang , Chen Wen-Cheng , Chen Miao-Fen
Published: April 2023

Supplementary Figure 6. Effect of Calcitriol treatments on the function and recruitment of MDSC in vivo.
Supplementary Methods from Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro
Authors: Wu Xuping , Sooman Linda , Wickström Malin , Fryknäs Mårten , Dyrager Christine , Lennartsson Johan , Gullbo Joachim
Published: April 2023

PDF file - 368K
Supplementary Figure Legends from Strengthening Context-Dependent Anticancer Effects on Non–Small Cell Lung Carcinoma by Inhibition of Both MET and EGFR
Authors: Zhang Yu-Wen , Staal Ben , Essenburg Curt , Lewis Steven , Kaufman Dafna , Vande Woude George F.
Published: April 2023

Supplementary Figure Legends - PDF file 35K, supplementary figure legends
Supplementary Figure 3 from Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro
Authors: Wu Xuping , Sooman Linda , Wickström Malin , Fryknäs Mårten , Dyrager Christine , Lennartsson Johan , Gullbo Joachim
Published: April 2023

PDF file - 44K, Figure S3 A: Survival-concentration curves for PPP in the phenotypic cell line panel. B: The survival indices for cells treated with PPT (16 nM) or PPP (5 μM) were highly correlated (p < 0.001).
Data Supplement from Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na
Authors: Mäki-Jouppila Jenni H.E. , Laine Leena J. , Rehnberg Jonathan , Narvi Elli , Tiikkainen Pekka , Hukasova Elvira , Halonen Pasi , Lindqvist Arne , Kallio Lila , Poso Antti , Kallio Marko J.
Published: April 2023

Supplementary Figure S1. The majority of rigosertib treated HeLa cells exhibit long mitotic arrest followed by cell death. Supplementary Figure S2. Centmitor-1 induces mitotic arrest followed by apoptosis. Supplementary Figure S3. Rigosertib treatment induces chromosome misalignment and multipolarity in HeLa cells. Supplementary Figure S4. SAC proteins BubR1 and Bub1 localize to the kinetochores of unaligned chromosomes in rigosertib treated HeLa cells. Supplementary Figure S5. High concentration of rigosertib induces microtubule depolymerisation in HeLa cells. Supplementary Figure S6. Impact of Cent-1 and rigosertib on microtubules in A549 cells expressing EGFP-alpha-tubulin. Supplementary Figure S7. Analysis of Plk1 localization and PI3K activity in Cent-1 and rigosertib treated HeLa cells. Legends for Supplementary Figures 1 through 7 and Supplementary Movies 1 through 5. Supplementary Methods.
Data Supplement from Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na
Authors: Mäki-Jouppila Jenni H.E. , Laine Leena J. , Rehnberg Jonathan , Narvi Elli , Tiikkainen Pekka , Hukasova Elvira , Halonen Pasi , Lindqvist Arne , Kallio Lila , Poso Antti , Kallio Marko J.
Published: April 2023

Supplemental Movie 2. Control HeLa H2B-GFP mCherry-tubulin cells undergo normal cell division. The representative cell forms a bipolar spindle and exhibits normal chromosome congression to the metaphase plate followed by cell division into two daughter cells (nuclear envelope breakdown to anaphase time is 38 min). The cell was treated with DMSO for 1 h before time-lapse filming started with 2 min frame capture interval. The numbers indicate time in h:min. H2B-GFP is coloured red and mCherry tubulin green.
Supplementary Figure 7 from Identification, Mechanism of Action, and Antitumor Activity of a Small Molecule Inhibitor of Hippo, TGF-β, and Wnt Signaling Pathways
Authors: Basu Dipanjan , Lettan Robert , Damodaran Krishnan , Strellec Susan , Reyes-Mugica Miguel , Rebbaa Abdelhadi
Published: April 2023

PDF - 70K, Respective contributions of AMPK and Lats1 in mediating the action of C19.
Supplementary Figure S3 from Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies
Authors: Tung Hsin-Yi , Su Yu-Cheng , Chen Bing-Mae , Burnouf Pierre-Alain , Huang Wei-Chiao , Chuang Kuo-Hsiang , Yan Yu-Ting , Cheng Tian-Lu , Roffler Steve R.
Published: April 2023

Comparison of the surface HER2 expression of different human cancer cell lines.
Supplementary Figure S1 from Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies
Authors: Tung Hsin-Yi , Su Yu-Cheng , Chen Bing-Mae , Burnouf Pierre-Alain , Huang Wei-Chiao , Chuang Kuo-Hsiang , Yan Yu-Ting , Cheng Tian-Lu , Roffler Steve R.
Published: April 2023

Outline of the hybrid antibody purification process.
Supplementary Figure 2 from Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
Authors: Wang Jing , Pursell Natalie W. , Samson Maria Elena S. , Atoyan Ruzanna , Ma Anna W. , Selmi Abdelkader , Xu Wanlu , Cai Xiong , Voi Maurizio , Savagner Pierre , Lai Cheng-Jung
Published: April 2023

PDF file - 140K, Changes in subcellular markers induced by treatment with CUDC-101 or erlotinib in parental and erlotinib-TR HCC827 cells.
Supplementary Table S2 from Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
Authors: Govindan Serengulam V. , Cardillo Thomas M. , Sharkey Robert M. , Tat Fatma , Gold David V. , Goldenberg David M.
Published: April 2023

PDF file - 60 KB, Reversed-phase HPLC analyses of cathepsin B incubates and buffer control incubates of ME-CL2A-SN-38, pH 5, 37 degrees Celsius. Values represent % of applied product.
Supplementary Table S1 from Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
Authors: Govindan Serengulam V. , Cardillo Thomas M. , Sharkey Robert M. , Tat Fatma , Gold David V. , Goldenberg David M.
Published: April 2023

PDF file - 59 KB, Reversed-phase HPLC analyses of cathepsin B incubates and buffer control incubates of ME-CL2E-SN-38, pH 5, 37 degrees Celsius. Values represent % of applied product.
Supplementary Materials and Methods from Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
Authors: Govindan Serengulam V. , Cardillo Thomas M. , Sharkey Robert M. , Tat Fatma , Gold David V. , Goldenberg David M.
Published: April 2023

PDF file - 98 KB
Supplementary Figure 3 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
Authors: Ning Yan , Gerger Armin , Zhang Wu , Hanna Diana L. , Yang Dongyun , Winder Thomas , Wakatsuki Takeru , Labonte Melissa J. , Stintzing Sebastian , Volz Nico , Sunakawa Yu , Stremitzer Stefan , El-Khoueiry Rita , Lenz Heinz-Josef
Published: April 2023

PDF - 56KB, Time-to-tumor recurrence (TTR) by PLS3 rs6643869 in USC cohort (Training set) stage II/III CRC male patients treated with 5-fluorouracil (5-FU)-based chemotherapy.
Supplementary Figure 4 from Leelamine Mediates Cancer Cell Death through Inhibition of Intracellular Cholesterol Transport
Authors: Kuzu Omer F. , Gowda Raghavendra , Sharma Arati , Robertson Gavin P.
Published: April 2023

PDF - 55K, Statins as cholesterol transport inhibitors are ineffective in inducing death of UACC 903 melanoma cells.
Supplementary Figure 2 from Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells
Authors: Happold Caroline , Roth Patrick , Silginer Manuela , Florea Ana-Maria , Lamszus Katrin , Frei Karl , Deenen Rene , Reifenberger Guido , Weller Michael
Published: April 2023

PDF file - 20KB, Affymetrix gene expression.
Supplementary Figure Legends from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy
Authors: Chen Xi , Díaz-Rodríguez Elena , Ocio Enrique M. , Paiva Bruno , Mortensen Deborah S. , Lopez-Girona Antonia , Chopra Rajesh , Miguel Jesús San , Pandiella Atanasio
Published: April 2023

PDF file - 29K
Supplementary Figure 7 from Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor–Induced DNA Damage and Apoptosis
Authors: Petruccelli Luca A. , Pettersson Filippa , del Rincón Sonia V. , Guilbert Cynthia , Licht Jonathan D. , Miller Wilson H.
Published: April 2023

PDF file - 1296K, PLZF-RARα expression enhances romidepsin-mediated down-regulation of BCL2 protein and vorinostat down-regulates Ape1 protein in Kasumi-1 cells.
Supplementary Figure 2 from BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
Authors: Kutluk Cenik Bercin , Ostapoff Katherine T. , Gerber David E. , Brekken Rolf A.
Published: April 2023

PDF - 118KB, Immunohistochemical evaluation and quantification of phospho-histone H3, Ki67, and cleaved caspase 3 in A549 and MIA PaCa-2 xenografts.
Supplementary Figure 1 from BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
Authors: Kutluk Cenik Bercin , Ostapoff Katherine T. , Gerber David E. , Brekken Rolf A.
Published: April 2023

PDF - 117KB, Supplemental data showing the activity of BIBF 1120 as a single agent in A549 xenografts.
Supplementary Table 4 from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
Authors: Fitzgerald Jonathan B. , Johnson Bryan W. , Baum Jason , Adams Sharlene , Iadevaia Sergio , Tang Jian , Rimkunas Victoria , Xu Lihui , Kohli Neeraj , Rennard Rachel , Razlog Maja , Jiao Yang , Harms Brian D. , Olivier Kenneth J. , Schoeberl Birgit , Nielsen Ulrik B. , Lugovskoy Alexey A.
Published: April 2023

PDF - 69K, Supplemental Table S4. List of the mechanistic model parameters and reactions.
Supplementary Tables 1 through 4 and Supplementary Figures 1 through 5 from In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
Authors: Tjin Tham Sjin Robert , Lee Kwangho , Walter Annette O. , Dubrovskiy Aleksandr , Sheets Michael , Martin Thia St. , Labenski Matthew T. , Zhu Zhendong , Tester Richland , Karp Russell , Medikonda Aravind , Chaturvedi Prasoon , Ren Yixuan , Haringsma Henry , Etter Jeff , Raponi Mitch , Simmons Andrew D. , Harding Thomas C. , Niu Deqiang , Nacht Mariana , Westlin William F. , Petter Russell C. , Allen Andrew , Singh Juswinder
Published: April 2023

PDF - 252K, Supplemental Table 1. Mass spectrometry on EGFR-L858R/T790M protein. Supplemental Table 2. EGFR modulation in A431, H1975 and HCC827 cells by compound 3. Supplemental Table 3. Kinase selectivity profile of compound 3, afatinib and WZ4002 at 1 ?M. Supplemental Table 4.Multi-dose level PK/PD study in H1975 tumor-bearing mice. Supplemental Figure 1. Signaling inhibition in EGFR wild-type (A431) and mutant EGFR NSCLC cells (H1975 and HCC827). Supplemental Figure 2. Prolonged duration of action on EGFR-L858R/T790M (A) and EGFR-DelE746-A750 (B) proteins. Supplemental Figure 3. Protein degradation (t1/2) of EGFR-L858R/T790M (A) and EGFR-DelE746-A750 (B) in H1975 and HCC827 cells, respectively. Supplemental Figure 4. Prolonged duration of action on EGFR-DelE746-A750 protein by erlotinib. Supplemental Figure 5. Time-dependent inhibition in EGFR mutant H1975 (A) and HCC827 (B) cells.
Supplementary Materials and Methods and Supplementary Figure Legends from In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
Authors: Tjin Tham Sjin Robert , Lee Kwangho , Walter Annette O. , Dubrovskiy Aleksandr , Sheets Michael , Martin Thia St. , Labenski Matthew T. , Zhu Zhendong , Tester Richland , Karp Russell , Medikonda Aravind , Chaturvedi Prasoon , Ren Yixuan , Haringsma Henry , Etter Jeff , Raponi Mitch , Simmons Andrew D. , Harding Thomas C. , Niu Deqiang , Nacht Mariana , Westlin William F. , Petter Russell C. , Allen Andrew , Singh Juswinder
Published: April 2023

PDF - 91K, Supplemental Materials and Methods and Legends for Supplementary Figures 1 through 5.
Supplementary Figures 1 - 2 from BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia
Authors: Pierceall William E. , Kornblau Steven M. , Carlson Nicole E. , Huang Xuelin , Blake Noel , Lena Ryan , Elashoff Michael , Konopleva Marina , Cardone Michael H. , Andreeff Michael
Published: April 2023

PDF file - 79K, Supplementary Figure 1. BH3 Profiling representative patient data; Supplementary Figure 2. BH3 Profiling for BH3 Peptides in AML NR and CR Patients.
Supplementary Figures 1 through 8 from Identification of Transmembrane Protein 98 as a Novel Chemoresistance-Conferring Gene in Hepatocellular Carcinoma
Authors: Ng Kevin Tak-Pan , Lo Chung Mau , Guo Dong Yong , Qi Xiang , Li Chang Xian , Geng Wei , Liu Xiao Bing , Ling Chang Chun , Ma Yuen Yuen , Yeung Wai Ho , Shao Yan , Poon Ronnie Tung-Ping , Fan Sheung Tat , Man Kwan
Published: April 2023

PDF - 924K, Supplementary Figure 1: Morphology and growth curves of MHCC97L, MHCC97L/CisR and MHCC97L/DoxR cells. Supplementary Figure 2: In vivo growth rate of MHCC97L, MHCC97L/CisR and MHCC97L/DoxR cells in nude mice. Supplementary Figure 3: Experimental flow for identification of chemoresistant targets. Supplementary Figure 4: Expression profiles of candidate genes in chemoresistant cells. Supplementary Figure 5: The persistence of TMEM98 expression after drug treatment. Supplementary Figure 6: The expression level of TMEM98 after transfection of TMEM98 siRNA. Supplementary Figure 7: MTT cytotoxic assay of PLC-pcDNA3.1 and PLC-TMEM98 cells in cisplatin or doxorubicin treatment. Supplementary Figure 8: MTT cytotoxic assay of MHCC97L-pcDNA3.1 and MHCC97L-TMEM98 cells under the treatment of sorafenib.
Supplementary Tables 1-4 from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo
Authors: Loddick Sarah A. , Ross Sarah J. , Thomason Andrew G. , Robinson David M. , Walker Graeme E. , Dunkley Tom P.J. , Brave Sandra R. , Broadbent Nicola , Stratton Natalie C. , Trueman Dawn , Mouchet Elizabeth , Shaheen Fadhel S. , Jacobs Vivien N. , Cumberbatch Marie , Wilson Joanne , Jones Rhys D.O. , Bradbury Robert H. , Rabow Alfred , Gaughan Luke , Womack Chris , Barry Simon T. , Robson Craig N. , Critchlow Susan E. , Wedge Stephen R. , Brooks A. Nigel
Published: April 2023

PDF - 329KB, Supplementary Table 1: TSQ Vantage mass spectrometry instrument settings. Supplementary Table 2: 4000 QTRAP mass spectrometry instrument settings. Supplementary Table 3: The half-life of AR for the first 6 hours following treatment calculated for both the N-terminal (i) and C-terminal (ii) AR peptides assuming exponential decay. Supplementary Table 4: Summary table of pharmacokinetics of ARD1 and AZD3514 in the mouse.